Email

xpchen@um.edu.mo

Tel

(853) 8822-4679

Office

N22-5002a

Consultation Hours

Mon: 10:00~11:00
Tue: 10:00~11:00

Web

Google ScholarGoogle Schloar

UM Scholar

UM Schloar

Xiuping CHEN 陳修平

Professor
Assistant Director (Chinese Medicine Education Development)

Academic Qualifications

  • Ph.D. Peking Union Medical College & Tsinghua University (2007)     
  • Med. Jining Medical College (2001)

Research Interests

  • Preclinical study of natural products regulating programmed cell death
    We mainly focuses on the preclinical development of naturals products that regulate programmed cell death (PCD). By using integrated platforms, we have identified naturals products with distinct mechanisms of action to induced PCD. We demonstrate that 2-methoxy-6-acetyl-7-methyljuglone (MAM), a type of quinone, induce cell-type dependent PCD dependent on ROS, caspase, RIPK1, or NQO1. We report for the first time that the form of PCD induced by MAM is distinct to any other types of PCD reported, and highly dependent on NQO1-mediated ROS production. We term this novel type of PCD as noptosis. We are still working on the underlying mechanisms and signaling that lead to noptosis. The therapetutic potential of noptosis is also being explored.     
  • Development of epithelial-mesenchymal transition inhibitors
    Epithelial-mesenchymal transition (EMT) is of pivotal importance in controlling tumor metastasis and organ fibrosis. By using the tumor growth factor β1-stimulated EMT model, we have identified a number of natural products as potent EMT inhibitors. Further study is on going to evaluate the therapeutic potential of these candidate EMT inhibitors on in vivo metasis and organ fibrosis models.    Postgraduate students and masters who wish to participate in our research projects on pharmacology and drug discovery are all welcomed. For further information, please contact Dr. Chen at xpchen@um.edu.moDr. Chen’s group WeChat subscription number is “药海撷英”.

Teaching

HSCI2010Pharmacology LabB.Sc. Course
GEST2003Exploring Chinese MedicineB.Sc. Course
CMED8010Advanced PharmacologyPostgraduate Course
CMED7002Introduction to Chinese MedicinePostgraduate Course
CMED7015Progress in Contemporary Study of Chinese MedicinePostgraduate Course

  • 17th SERVIER Young Pharmacologist Award (2013)
  • Macao Science and Technology Awards (Second prize) (2012)(3rd)
  • Macao Science and Technology Awards (Second prize) (2014)(5th)
  • Science and Technology Award of Chinese Association for Laboratory Animal Sciences (Second prize) (2016)(2nd)

Journal: Chen has > 150 SCI publications in peer-reviewed journals with >11,000 citations and the h-index is 55. (Google scholar, Sep 2022) (*corresponding author)

  1. Zhong B, Zhao L, Yu J, Hou Y, Ai N, Lu JJ, Ge W, Chen X*. Exogenous iron impairs the anti-cancer effect of ascorbic acid both in vitro and in vivo. J Adv Res. 2022 Jun 29:S2090-1232(22)00149-7. (IF:12.8)
  2. Hou Y, Liu R, Xia M, Sun C, Zhong B, Yu J, Ai N, Lu JJ, Ge W, Liu B, Chen X*. Nannocystin ax, an eEF1A inhibitor, induces G1 cell cycle arrest and caspase-independent apoptosis through cyclin D1 downregulation in colon cancer in vivo. Pharmacol Res. 2021 Sep 7;173:105870. (IF:10.3)
  3. Wang M, Lin L, Lu JJ, Chen X*. Pharmacological review of isobavachalcone, a naturally occurring chalcone. Pharmacol Res. 2021 Mar;165:105483. (IF:10.3)
  4. Wang X, Wang X, Zhu Y, Chen X*. ADME/T-based strategies for paraquat detoxification: Transporters and enzymes. Environ Pollut. 2021 Sep 9;291:118137.(IF: 10)
  5. Zhong B, Yu J, Hou Y, Ai N, Ge W, Lu JJ, Chen X*. A novel strategy for glioblastoma treatment by induction of noptosis, an NQO1-dependent necrosis. Free Radic Biol Med. 2021 Apr;166:104-115.(IF: 8.1)
  6. Yu J, Zhong B, Zhao L, Hou Y, Wang X, Chen X*. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors Necrostatin-1 (Nec-1) and 7-Cl-O-Nec-1 (Nec-1s) are potent inhibitors of NAD(P)H: Quinone oxidoreductase 1 (NQO1). Free Radic Biol Med. 2021 Sep;173:64-69.(IF: 8.1)
  7. Yu J, Zhong B, Xiao Q, Du L, Hou Y, Sun HS, Lu JJ, Chen X*. Induction of programmed necrosis: A novel anti-cancer strategy for natural compounds. Pharmacol Ther. 2020 Oct;214:107593. (IF: 13.4)
  8. Sun C, Zhao W, Wang X, Sun Y, Chen X*. A pharmacological review of dicoumarol: An old natural anticoagulant agent. Pharmacol Res. 2020 Oct;160:105193. (IF:10.3)
  9. Yu J, Zhong B, Jin L, Hou Y, Ai N, Ge W, Li L, Liu S, Lu JJ, Chen X*. 2-Methoxy-6-acetyl- 7-methyljuglone (MAM) induced programmed necrosis in glioblastoma by targeting NAD(P)H: Quinone oxidoreductase 1 (NQO1). Free Radic Biol Med. 2020 May 20;152:336-347. (IF: 8.1)
  10. Zhao W, Li C, Zhang H, Zhou Q, Chen X, Han Y, Chen X*. Dihydrotanshinone I Attenuates Plaque Vulnerability in Apolipoprotein E-Deficient Mice: Role of Receptor-Interacting Protein 3. Antioxid Redox Signal. 2020 Jun 4.(IF:7.5)
  11. Liu X, Zhang Y, Gao H, Hou Y, Lu JJ, Feng Y, Xu Q, Liu B, Chen X*. Induction of an MLKL mediated non-canonical necroptosis through reactive oxygen species by tanshinol A in lung cancer cells. Biochem Pharmacol. 2020 Jan;171:113684.(IF: 6.1)
  12. Wu C, Chen J, Yang R, Duan F, Li S*, Chen X*. Mitochondrial protective effect of neferine through the modulation of Nrf2 signalling in ischemic stroke. Br J Pharmacol. 2019 Feb;176(3):400-415. (IF: 9.5)
  13. Sun W, Yu J, Gao H, Wu X, Wang S, Hou Y, Lu JJ, Chen X*. Inhibition of Lung Cancer by 2-Methoxy-6-Acetyl-7-Methyljuglone Through Induction of Necroptosis by Targeting Receptor- Interacting Protein 1. Antioxid Redox Signal. 2019 Jul 10;31(2):93-108. (IF:7.5)
  14. Chen X*, Yu J, Zhong B, Lu J, Lu JJ, Li S, Lu Y. Pharmacological activities of dihydrotanshinone I, a natural product from Salvia miltiorrhiza Bunge. Pharmacol Res. 2019 Jul;145:104254. (IF:10.3)
  15. Sun W, Wang S, Zhao W, Wu C, Guo S, Hongwei G, Hongxun T, Lu JJ, Wang Y, Chen X*. Chemical Constituents and Biological Research on Plants in the Genus Curcuma. Crit Rev Food Sci Nutr. 2017 ; 57(7):1451-1523.(IF: 11.2)
  16. Zhao W, Feng H, Sun W, Liu K, Lu J, Chen X*. Tert-butyl hydroperoxide (t-BHP) induced apoptosis and necroptosis in endothelial cells: Roles of NOX4 and mitochondrion. Redox Biology. 2017 Jan 5;11: 524 -534. (IF:10.8)
  17. Gao H, Cui Y, Kang N, Liu X, Liu Y, Zou Y, Zhang Z, Li X, Yang S, Li J, Wang C, Xu QM*, Chen X*. Isoacteoside, a dihydroxyphenylethyl glycoside, exhibits anti-inflammatory effects through blocking TLR4 dimerization. Br J Pharmacol. 2017 Sep; 174(17):2880-2896. (IF: 9.5)
  18. Gao H, Liu X, Sun W, Kang N, Liu Y, Yang S, Xu QM, Wang C, Chen X*. Total tanshinones exhibit anti-inflammatory effects through blocking TLR4 dimerization via the MyD88 pathway. Cell Death Dis. 2017 Aug 17;8(8):e3004.(IF: 9.7)
  19. Sun W, Wu X, Gao H, Yu J, Zhao W, Lu JJ, Wang J, Du G, Chen X*. Cytosolic calcium mediates RIP1/RIP3 complex-dependent necroptosis through JNK activation and mitochondrial ROS production in human colon cancer cells. Free Radic Biol Med. 2017 Jul;108:433-444. (IF: 8.1)
  20. Sun W, Bao J, Lin W, Gao H, Zhao W, Zhang Q, Leung CH, Ma DL, Lu J, Chen X*. 2-Methoxy-6- acetyl-7-methyljuglone (MAM), a natural naphthoquinone, induces NO-dependent apoptosis and necroptosis by H(2)O(2)-dependent JNK activation in cancer cells. Free Radic Biol Med. 2016 Jan 21;92:61-77. (IF: 8.1)
  21. Wu C, Zhao W, Zhang X, Chen X*. Neocryptotanshinone inhibits lipopolysaccharide-induced inflammation in RAW264.7 macrophages by suppression of NF-κB and iNOS signaling pathways. Acta Pharm Sin B. 2015 Jul;5(4):323-9. (IF: 14.9)
  22. Chen X*, Guo J, Bao J, Lu J, Wang Y. The anticancer properties of Salvia miltiorrhiza Bunge (Danshen): a systematic review. Med Res Rev. 2014 Jul;34(4):768-94.(IF: 12.4)
  23. Chen X*, Lu J, Bao J, Guo J, Shi J, Wang Y*. Adiponectin: a biomarker for rheumatoid arthritis? Cytokine Growth Factor Rev. 2013 Feb;24(1):83-9. (IF: 17.7)
  24. Chen X, Zhang H, McAfee S, Zhang C*. The reciprocal relationship between adiponectin and LOX-1 in the regulation of endothelial dysfunction in ApoE knockout mice. Am J Physiol Heart Circ Physiol. 2010; 299(3): H605-12. (IF:5.1)

Book

  1. 陳修平。(2019). 宋代絕句精華賞析。澳門澳門人出版社。

Book Chapter

  1. Chen X. (2022).Carnosol. Antioxidants Effects in Health, p117-120. Elsevier.
  2. Chen X. (2021).藥理學細胞模型的製備. 實驗藥理學，p111-115. 高等教育出版社。
  3. Yu J, Zhong B, Chen X. (2020). Induction of programmed necrosis by phytochemicals in colorectal cancer. Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies. Elsevier.
  4. Chen X, Wang J, Du G. (2018). 苦楝皮. 中藥材“毒”古今研究概評, p234-237. 中國醫藥科技出版社。
  5. Chen X, Wang J, Du G. (2018). 川楝子. 中藥材“毒”古今研究概評, p121-126. 中國醫藥科技出版社。
  6. Sun W, Du L, Wang S, Chen X, Du G. (2018). Shikonin. Natural small molecule drugs from plants (pp.731-736). Springer.
  7. Yu J, Du L, Chen X, Wang S, Du G. (2018). Cissampelini Methiodidum. Natural small molecule drugs from plants (pp.215-219). Springer.
  8. Sun W,Du L, Chen X. (2018).紫草素.天然小分子藥物. p319-321.人民衛生出版社。
  9. Yu J, Chen X. (2018). 傣肌松. 天然小分子藥物. p141-143. 人民衛生出版社。

Granted:

  1. 陳修平 陸遠富 郭艷玲。甲基蓮心堿在製備治療潰瘍性結腸炎的藥物中的應用。中國專利，授權公告號 CN 108888622 B
  2. 陳修平 陸遠富 石京山 郭艷玲。二氫丹參酮Ⅰ在製備治療潰瘍性結腸炎的藥物中的應用。中國專利， 授權公告號 CN 107468680 B
  3. 孫毅毅 鐘玲 林東 陳修平。一種脂聯素受體配基及激動劑的篩選方法。中國專利，授權公告號 CN 102879587 B

Pending：

  1. 陳修平 葛偉 侯瑩。隱丹參酮類物質及其聯用組合物的應用。中國專利，申請號202210731322.8
  2. 陳修平 葛偉 余潔 陸金健 鐘冰玲。2-甲氧基-6-乙醯基-7-甲基胡桃酮的新的應用。申請號202110213204.3
  3. 陳修平 趙文文。氯硝柳胺的新應用。中國專利，申請號：202110214182.2
  4. 陳修平 張藝嬴 王旭玫。雙香豆素在抗腫瘤中的應用。中國專利，申請號：202011165985.5
  5. 陳修平 葛偉 余潔 鐘冰玲。2-甲氧基-6-乙醯基-7-甲基胡桃酮的應用。中國專利，申請號：201910964122.5
  6. 路嘉宏 陳修平 董雨 駱瑋瑋。川楝素在腫瘤治療中的應用。中國專利，申請號：201910622457.9
  7. 李韶菁 陳修平 吳傳鴻。一種化合物治療咽炎的新用途。中國專利，申請號：201811343982.9
  8. 李韶菁 陳修平 吳傳鴻。一種化合物治療缺血性腦病的新用途。中國專利，申請號：201711046476.9

  • Council, Chinese Pharmacological Society (CPS) (中國藥理學會)
  • Committee member, Professional Committee of Traditional Chinese Medicine and Natural Medicine Pharmacology of CPS (中國藥理學會-中藥與天然藥物藥理專業委員會)
  • Member, Chinese Society for Cell Biology (中國細胞生物學會)

  • Grant Reviewer for National Science Foundation of China (NSFC), Research Grants Council (RGC) of Hong Kong, ITMO Cancer of the French National Alliance for Life and Health Sciences (AVIESAN) jointly with the French National Cancer Institute (INCa), National Science Centre Poland, etc.
  • Manuscript Reviewer for Biomaterials, Pharmacology & Therapeutics, Redox Biology, Acta Pharmaceutica Sinica B, Medicinal Research Reviews, British Journal of Pharmacology, etc.